Knight Therapeutics Acquires Exclusive Marketing Rights to Nerlynx in Canada
News
Breast cancer treatment Nerlynx (neratinib) will be exclusively commercialized in Canada by Knight Therapeutics, under an agreement with the therapy’s developer, Puma Biotechnology. Nerlynx is currently being reviewed by Health Canada as a ... Read more